eXTReMe Tracker

New and Updated Clinical Ebola Vaccine Trials

Latest Ebola vaccine studies updated or received at ClinicalTrials.gov. Only open studies, recruiting or not yet recruiting, are shown found by a search using the keyword: "ebola"

  • Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRC

    Nov 5, 2019 | 18:00 pm

    Condition:  Ebola Virus DiseaseIntervention:  Biological: Ad26.ZEBOV, MVA-BN-Filo vaccineSponsors:  London School of Hygiene and Tropical Medicine;   Epicentre;   Ministère de la Santé de la RDC;   Médecins Sans Frontières, France;   Coalition for Epidemic Preparedness Innovations;   Janssen Vaccines & Prevention B.V.;   Public Health EnglandNot yet recruiting

  • Ebola Sudan Chimpanzee Adenovirus Vector Vaccine in Healthy Adults

    Aug 1, 2019 | 18:00 pm

    Condition:  Ebola VirusIntervention:  Biological: cAd3-EBO S vaccineSponsors:  National Institute of Allergy and Infectious Diseases (NIAID);   US Military HIV Research ProgramActive, not recruiting

  • Ebola Vaccine Trial (Ad26.ZEBOV/MVA-BN-Filo)

    Jul 22, 2019 | 18:00 pm

    Condition:  Ebola Virus DiseaseIntervention:  Drug: Ad26.ZEBOV/MVA-BN-FiloSponsors:  MRC/UVRI Uganda Research Unit on Aids;   Epicentre, Paris, France and Mbarara, Uganda;   Janssen Pharmaceutica N.V., Belgium;   Coalition for Epidemic Preparedness InnovationsRecruiting

  • Investigational Therapeutics for the Treatment of People With Ebola Virus Disease

    Oct 25, 2018 | 18:00 pm

    Condition:  Ebola VirusInterventions:  Drug: ZMapp;   Drug: Remdesivir;   Drug: MAb114;   Drug: REGN-EB3Sponsor:  National Institute of Allergy and Infectious Diseases (NIAID)Recruiting

  • Persistence of the Immune Response After Immunisation With Ebola Virus Vaccines

    May 4, 2017 | 18:00 pm

    Condition:  Ebola Virus DiseaseIntervention:  Biological: Previously exposed to Ebola vaccineSponsors:  University of Oxford;   University of GlasgowEnrolling by invitation

  • PREVAIL VI: Identification of Host Genetic Factors Underlying Ebola Virus Disease Risk, Mortality, Long-term Sequelae, Viral RNA Persistence, Humoral Immunity, and Ebola Vaccine Response

    Apr 4, 2017 | 18:00 pm

    Condition:  Ebola Virus DiseaseIntervention:  Sponsor:  National Institute of Allergy and Infectious Diseases (NIAID)Completed

  • African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-Ebola

    Jan 26, 2017 | 18:00 pm

    Condition:  EbolaInterventions:  Biological: V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine;   Other: SalineSponsors:  Dalhousie University;   Merck Sharp & Dohme Corp.;   International Development Research Centre, Canada;   Canadian Immunization Research NetworkRecruiting

  • Partnership for Research on Ebola VACcinations

    Aug 23, 2016 | 18:00 pm

    Condition:  Ebola Virus DiseaseInterventions:  Biological: Ad26.ZEBOV;   Biological: MVA-BN-Filo;   Biological: rVSVΔG-ZEBOV-GP;   Biological: Placebo;   Biological: rVSV boostSponsors:  National Institute of Allergy and Infectious Diseases (NIAID);   The Liberia-US Clinical Trials Partnership Program, Partnership for Research on Ebola Virus in Liberia Project (PREVAIL);   Institut National de la Santé Et de la Recherche Médicale, France;   London School of Hygiene and Tropical MedicineActive, not recruiting

  • GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen

    Jun 29, 2016 | 18:00 pm

    Condition:  EbolaInterventions:  Drug: GS-5734;   Other: Placebo ComparatorSponsor:  National Institute of Allergy and Infectious Diseases (NIAID)Completed

  • Trial to Evaluate Safety and Immunogenicity of an Ebola Zaire Vaccine in Healthy Adults

    Mar 24, 2016 | 17:00 pm

    Condition:  Ebola Virus DiseaseInterventions:  Biological: Ebola Vaccine - low dose;   Biological: Ebola Vaccine - mid dose;   Biological: Ebola Vaccine - high dose;   Biological: PlaceboSponsors:  Profectus BioSciences, Inc.;   Accelovance;   United States Department of DefenseCompleted

  • A Booster Dose of Ad5-EBOV in Healthy Adults After Primary Immunization

    Aug 27, 2015 | 18:00 pm

    Condition:  Ebola Virus DiseaseInterventions:  Biological: 4×10^10vp/1ml Ebola Zaire vaccine (Ad5-EBOV);   Biological: 1.6×10^11vp/2ml Ebola Zaire vaccine (Ad5-EBOV);   Biological: placeboSponsors:  Jiangsu Province Centers for Disease Control and Prevention;   Beijing Institute of Biotechnology;   Tianjin Cansino Biotechnology IncCompleted

  • Ebola Virus Disease Survivors: Clinical and Immunologic Follow-up

    May 1, 2015 | 18:00 pm

    Condition:  Ebola Virus DiseaseIntervention:  Sponsor:  National Institute of Allergy and Infectious Diseases (NIAID)Active, not recruiting

  • STRIVE (Sierra Leone Trial to Introduce a Vaccine Against Ebola)

    Mar 4, 2015 | 18:00 pm

    Condition:  Hemorrhagic Fever, EbolaIntervention:  Biological: rVSVΔG-ZEBOVSponsors:  Centers for Disease Control and Prevention;   University of Sierra Leone;   Ministry of Health and Sanitation, Sierra Leone;   Department of Health and Human Services;   eHealth AfricaCompleted

  • Clinical Trial of Ebola Vaccines cAd3-EBO, cAd3-EBOZ and MVA-EbolaZ in Healthy Adults in Uganda

    Feb 3, 2015 | 18:00 pm

    Condition:  Hemorrhagic Fever, EbolaInterventions:  Biological: cAd3-EBOZ;   Biological: cAd3-EBO;   Biological: MVA-EbolaZSponsors:  National Institute of Allergy and Infectious Diseases (NIAID);   US Military HIV Research Program;   The Emmes Company, LLCCompleted

  • Partnership for Research on Ebola Vaccines in Liberia (PREVAIL)

    Jan 26, 2015 | 18:00 pm

    Condition:  Ebola VirusInterventions:  Biological: VSVG-ZEBOV;   Biological: ChAd3-EBO Z;   Biological: PlaceboSponsor:  National Institute of Allergy and Infectious Diseases (NIAID)Active, not recruiting

  • Emergency Evaluation of Convalescent Plasma for Ebola Viral Disease (EVD) in Guinea

    Jan 19, 2015 | 18:00 pm

    Condition:  Hemorrhagic Fever, EbolaIntervention:  Other: Convalescent PlasmaSponsors:  Institute of Tropical Medicine, Belgium;   National Blood Transfusion Centre (NBTC), Conakry, Guinea;   Gamal Abdel Nasser University of Conakry;   National Center for Training and Research of Maferinyah, Guinea;   Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo;   University of Oxford;   University of Liverpool;   London School of Hygiene and Tropical Medicine;   Aix Marseille Université;   UBIVE, Institut Pasteur, Paris, France;   Institut National de la Santé Et de la Recherche Médicale, France;   Etablissement Français du Sang;   Belgian Red Cross;   Institut Pasteur, Dakar, Sénégal;   Médecins Sans Frontières, Belgium;   World Health Organization;   International Severe Acute Respiratory and Emerging Infection ConsortiumCompleted

  • A Phase I Clinical Trial to Evaluate the Ebola Adenovirus Vector Vaccine (Ad5-EBOV) in Healthy Adults.

    Dec 25, 2014 | 18:00 pm

    Condition:  Ebola Virus DiseaseInterventions:  Biological: Low dose Ebola Zaire vaccine (Ad5-EBOV);   Biological: High dose Ebola Zaire vaccine (Ad5-EBOV);   Biological: placebo (one dose);   Biological: placebo (two doses)Sponsors:  Jiangsu Province Centers for Disease Control and Prevention;   Beijing Institute of Biotechnology;   Tianjin Cansino Biotechnology IncCompleted

  • Phase 1 Trial of Ebola Vaccine in Mali

    Oct 17, 2014 | 18:00 pm

    Conditions:  Ebola Virus Disease;   Hemorrhagic FeverInterventions:  Biological: Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z;   Biological: Booster-MVA-BN® Filo or saline placeboSponsors:  University of Maryland, Baltimore;   Wellcome Trust;   National Institute of Allergy and Infectious Diseases (NIAID);   Leidos Biomedical Research, Inc.Completed

  • A Study to Assess New Ebola Vaccines, cAd3-EBO Z and MVA-BN® Filo

    Sep 16, 2014 | 18:00 pm

    Conditions:  Ebola;   Ebola ZaireInterventions:  Biological: cAd3-EBO Z at 1 x 10^10 vp;   Biological: cAd3-EBO Z at 2.5 x 10^10 vp;   Biological: cAd3-EBO Z at 5 x 10^10 vp;   Biological: 4.4x10^8 TCID50s MVA-BN® Filo;   Biological: 2.2x10^8 TCID50s MVA-BN® Filo;   Biological: 4.4 x 10^7 TCID50s MVA-BN® FiloSponsors:  University of Oxford;   Wellcome Trust;   National Institute of Allergy and Infectious Diseases (NIAID)Completed

  • Evaluating an Ebola and a Marburg Vaccine in Uganda

    Oct 19, 2009 | 18:00 pm

    Conditions:  Ebola Virus Disease;   Marburg Virus DiseaseInterventions:  Biological: Ebola vaccine;   Biological: Marburg vaccine;   Other: Placebo injectionSponsor:  National Institute of Allergy and Infectious Diseases (NIAID)Completed



Ebola News